Nervgen Pharma Corporation News - NGEN

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NGEN

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NGEN Canada NewsWire VANCOUVER...

Canadian Investment Regulatory Organization Trade Resumption - NGEN

Canadian Investment Regulatory Organization Trade Resumption - NGEN Canada NewsWire VANCOUVER, BC, March 21, 2024 VANCOUVER, BC, March 21, 2024...

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING Canada NewsWire VANCOUVER, BC, March 21, 2024 /NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE...

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NGEN

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NGEN Canada NewsWire VANCOUVER, BC...

Canadian Investment Regulatory Organization Trading Halt - NGEN

Canadian Investment Regulatory Organization Trading Halt - NGEN Canada NewsWire VANCOUVER, BC, March 21, 2024 VANCOUVER, BC, March 21, 2024 /CNW/...

Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies

For anyone with a spinal cord injury (SCI), time is of the essence. The typical treatment scenario involves immobilization and surgery as quickly...

Small Company Working on Big Breakthrough in Treating Spinal Cord Injuries

Spinal cord injuries (SCI) can be devastating, and they can lead to a loss of mobility, sensation, and independence. There is no cure for SCI, and...

Life Science Investor Forum Agenda Announced for June 22nd

NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University

The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents...

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation

Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nervgen Pharma Corporation (NGEN)

Professional-Grade Tools, for Individual Investors.

NGEN News

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NGEN

Canadian Investment Regulatory Organization Trade Resumption - NGEN

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NGEN

Canadian Investment Regulatory Organization Trading Halt - NGEN

Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies

Small Company Working on Big Breakthrough in Treating Spinal Cord Injuries

Life Science Investor Forum Agenda Announced for June 22nd

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation

L'OCRCVM permet la reprise de la négociation - NGEN

IIROC Trading Resumption - NGEN

Suspension de la négociation par l'OCRCVM - NGEN

IIROC Trading Halt - NGEN

Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nervgen Pharma Corporation (NGEN) News

Nervgen Pharma Corporation (NGEN)

Professional-Grade Tools, for Individual Investors.

NGEN News

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - NGEN

Canadian Investment Regulatory Organization Trade Resumption - NGEN

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - NGEN

Canadian Investment Regulatory Organization Trading Halt - NGEN

Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies

Small Company Working on Big Breakthrough in Treating Spinal Cord Injuries

Life Science Investor Forum Agenda Announced for June 22nd

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation

L'OCRCVM permet la reprise de la négociation - NGEN

IIROC Trading Resumption - NGEN

Suspension de la négociation par l'OCRCVM - NGEN

IIROC Trading Halt - NGEN

Discussion

Your Recent History